Evidence map›Paper›PMID 42332334›Full record

ReviewJournal of the Egyptian National Cancer Institute2026

Tissue engineering driven regeneration in oral squamous cell carcinoma: from biomaterials to precision gene editing.

B Deva Darshinii, N Subhapradha, S Raghavi, K Anbarasu

Abstract readReview
In one paragraph

Review in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

B Deva DarshiniiSaveetha Institute of Medical And Technical Sciences, Chennai, India.
N SubhapradhaSaveetha Institute of Medical And Technical Sciences, Chennai, India.
S RaghaviSaveetha Institute of Medical And Technical Sciences, Chennai, India.
K AnbarasuSaveetha Institute of Medical And Technical Sciences, Chennai, India. anbarasuk.sse@saveetha.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral cancer is a significant global health challenge, ranking as the sixth most prevalent cancer worldwide, with approximately 377,000 new cases diagnosed annually. The high morbidity and mortality rates are largely attributed to tobacco and alcohol use. While conventional treatments such as surgery, radiation, and chemotherapy have improved survival rates, they often lead to unfavourable aesthetic and functional outcomes. Tissue engineering offers a promising alternative, providing regenerative solutions aimed at restoring both oral function and appearance. By integrating biomaterials, biological systems, and engineering principles, tissue engineering enables the creation of functional tissue replacements. The current review examines different t pathways the potential applications of autologous tissue, oral cancer cell lines, CRISPR, gene-editing technologies, and epigenetic modifications for tissue regeneration. Advanced scaffold technologies that mimic the natural extracellular matrix, along with stem cell-based therapies and bioactive molecules, are employed to support tissue growth and differentiation. Mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs) show significant potential in regenerating hard and soft oral tissues, while also targeting cancer stem cells (CSCs) to prevent recurrence. Furthermore, innovative technologies like 3D bio printing, combined with vascularization strategies, hold promise for developing patient-specific tissue constructs for reconstructive procedures. In conclusion, tissue engineering offers transformative potential for oral cancer treatment, presenting regenerative therapies that can significantly enhance patient outcomes and quality of life.

Indexed as

Biocompatible MaterialsCarcinoma, Squamous CellGene EditingMouth NeoplasmsRegenerationTissue EngineeringAnimalsHumansTissue ScaffoldsBiocompatible Materials3D bio printingOral cancerOral tissue regenerationRegenerative medicineTissue engineering

Identifiers

PMID42332334
PMCPMC13313296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.